Peptide record

TPDB92312

Longicalycinin A Antibacterial Anticancer Antifungal Antiparasitic Toxicity modified_plain modified
5 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB92312
Longicalycinin A
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CancerPPD 2.0 CAFPdb dbAMP
modified_plain
Yes
A 5-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from Peptipedia, CancerPPD 2.0, CAFPdb, and other sources, with an available 3D structural model.
C-terminal: Cyclized N-terminal: Cyclized
Sequence
FYPFG
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
5 reviewed residue count
Cyclized Activity
L Activity
Cyclic Activity
Cyclized Activity
Anticancer Activity
Dianthus superbus Synthetic Activity
Evidence Records 5 records
Evidence 1 Activity

Activity

IC50
IC50 = 13.52 µg/ml
Anticancer
13.52 µg/mL

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

CTC50
CTC50 = 2.62 µM
Anticancer
2.62 µM

Target

Lung Cancer
DLA cell line
Thymus

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
Evidence 3 Activity

Activity

CTC50
CTC50 = 6.17 µM
Anticancer
6.17 µM

Target

Breast Cancer
EAC cell Line
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
Evidence 4 Activity

Activity

IC50
IC50 = 10.45 ± 0.0042 µg/ml
Anticancer
10.45

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020
Evidence 5 Activity

Activity

IC50
IC50 = 11.87 ± 0.0021 µg/ml
Anticancer
11.87

Target

Colorectal Cancer
HT-29
Colon

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2020